A multicenter study for validation of biomarkers and observational study for immune regulatory mechanisms in Juvenile Dermatomyositis

A multicenter study for validation of biomarkers and observational study for immune regulatory mechanisms in Juvenile Dermatomyositis - Biomarkers and immunoregulatory mechanisms in JDM

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON50706

Enrollment

365

Registered

2014-11-04

Start date

2015-06-22

Completion date

Unknown

Last updated

2026-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Juvenile Dermatomyositis Rheumatic muscle disease

Interventions

None

Eligibility

Age

2 Years to 99 Years

Inclusion criteria

Inclusion criteria: Juvenile Dermatomyositis: - Consenting to participate, via signed informed consent  - Diagnosis of JDM according to Bohan and Peter criteria and/or EULAR/ACR classification criteria. - Age < 18 years S4S (non-inflammatory muscle disease) controls:  - Consenting to participate, via signed informed consent  - Age < 18 years  - Diagnosis of congenital myopathy, muscular dystrophy or mitochondrial myopathy or other non-inflammatory myopathies or neuromuscular diseases Adult idiopathic-inflammatory myopathies: - Consenting to participate, via signed informed consent  - Definite idiopathic-inflammatory myopathy according to EULAR/ACR classification criteria - Myositis overlap syndromes - Age >=18 yrs Systemic autoimmune diseases:- Consenting to participate, via signed informed consent                                                                                                - Age < 18 years - Diagnosis of systemic lupus erythematodes (SLE), mixed connective tissue disease (MCTD), overlap syndromes, scleroderma/morphea, vasculitis, or other systemic autoimmune disease. Healthy controls: - Consenting to participate, via signed informed consent  - Age <18 years

Exclusion criteria

Exclusion criteria: In all groups: No informed consent S4S disease controls: Chronic inflammatory diseases Healthy controls: Immune-mediated, neurological or metabolic diseases

Design outcomes

Primary

Measure	Time frame
With this study we want to determine the applicability of three proteins as biomarkers to assess disease activity in Juvenile dermatomyositis.	—

Secondary

Measure	Time frame
In addition we want to look into detail in the role of IL-18, CCL2, CCL4, CCL19, CCL27, CXCL10, CXCL13, TNFR1, TNFR2, galectin-9 and other potential biomarkers in the immunopathogenesis of JDM in relation to other systemic autoimmune diseases.	—

Countries

Canada, Netherlands

Contacts

Public ContactJ.W.N. Marsden

Universitair Medisch Centrum Utrecht

j.w.n.marsden@umcutrecht.nl+31 88 75 540 03

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Mar 20, 2026